4,5-二苯胺邻苯二甲酰亚胺 | 157168-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 4,5-二苯胺邻苯二甲酰亚胺
• 英文名称: 4,5-Bis(phenylamino)-1H-isoindole-1,3(2H)-dione
• 英文别名: 4,5-dianilinoisoindole-1,3-dione
• CAS: 157168-02-0
• 化学式: C₂₀H₁₅N₃O₂
• 分子量: 329.4
• InChiKey: IEQGCIBXRKUBNN-UHFFFAOYSA-N

物化性质

• 熔点：
  >185°C (dec.)
• 溶解度：
  二甲基亚砜：~30 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 安全说明：
  S36/37

文献信息

• ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR RECEPTOR
  申请人：Shang Yonglei

  公开号：US20090068110A1

  公开（公告）日：2009-03-12

  The invention provides various antibodies that bind to insulin-like growth factor-I receptor (IGF-1R), methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, cancer or aging. The antibodies include murine, chimeric, and humanized antibodies.

  这项发明提供了各种结合胰岛素样生长因子-I受体（IGF-1R）的抗体，制备这种抗体的方法，含有这种抗体的组合物和制品，以及它们在治疗癌症或衰老等方面的用途。这些抗体包括小鼠抗体、嵌合抗体和人源化抗体。
• HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
  申请人：Ye Weilan

  公开号：US20100285009A1

  公开（公告）日：2010-11-11

  The present invention concerns antibodies to EGFL7 and the uses of same.

  本发明涉及针对EGFL7的抗体以及其用途。
• Homogeneous humanized antibodies against JAM-A that inhibit proliferation
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP2455403A1

  公开（公告）日：2012-05-23

  The present invention relates to humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the invention relates to anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The invention also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The invention also relates to a method for the preparation of such humanized antibodies.

  本发明涉及能够抑制肿瘤生长的人源化抗体，以及编码这种抗体的氨基酸和核酸序列。从一个方面来看，该发明涉及能够抑制肿瘤生长的抗JAM-A同源化人源化抗体。该发明还包括将这种抗体用作预防和/或治疗癌症的药物，以及包含这种抗体与其他抗癌化合物组合的组合物。该发明还涉及一种制备这种人源化抗体的方法。
• Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
  申请人：Pharmacia Corporation

  公开号：US20040127470A1

  公开（公告）日：2004-07-01

  The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

  本发明涉及一种新型的预防和/或治疗肿瘤疾病的方法，通过向需要此类预防或治疗的受试者施用至少一种Cox-2抑制剂与EGF受体拮抗剂的组合物来实现。同时还描述了组合物、制药组合物和试剂盒。
• Topical compositions for the treatment of hyperproliferative skin disease
  申请人：CIBA-GEIGY AG

  公开号：EP0783887A2

  公开（公告）日：1997-07-16

  A composition suitable for topical administration in treatment of a hyperproliferative skin disease which is a gel comprising (A) a compound of formula wherein A1 and A2 are each independently of the other hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, acyl, lower alkylsulfonyl or arylsulfonyl; or wherein A1 and A2 together form unsubstituted or lower alkyl- or hydroxy-substituted lower alkylene; Ar1 and Ar2 are each independently of the other aryl, heteroaryl or unsubstituted or substituted cycloalkyl; the group -C(=X)- is -C(=O)-, -C(=S)-, -CH2- or -C(=CR1R2)- wherein R1 and R2 are each independently of the other hydrogen or lower alkyl; and R is hydrogen, lower alkyl, aryl-lower alkyl, aryl, amino, hydroxy or lower alkoxy; with the proviso that R is other than phenyl when A1 and A2 are hydrogen, Ar1 and Ar2 are phenyl and the group -C(=X)- is -C(=O)-; or a pharmaceutically acceptable salt thereof when a salt-forming group is present; (B)a C1-C4 alkyl monoether of diethyleneglycol, (C) a gelling agent and (D) a solvent which is miscible with (B).

  一种适用于局部用药治疗过度增生性皮肤病的组合物，它是一种凝胶，包含 (A) 式中的化合物 其中A1和A2各自独立地为氢、低级烷基、低级烯基、低级炔基、芳基、酰基、低级烷基磺酰基或芳基磺酰基；或其中A1和A2共同形成未取代的或低级烷基或羟基取代的低级亚烷基；Ar1和Ar2各自独立地为芳基、杂芳基或未取代或取代的环烷基；基团-C(=X)-为-C(=O)-、-C(=S)-、-CH2-或-C(=CR1R2)-，其中R1和R2各自独立地为氢或低级烷基；和 R 是氢、低级烷基、芳基-低级烷基、芳基、氨基、羟基或低级烷氧基；但当 A1 和 A2 是氢、Ar1 和 Ar2 是苯基且基团-C(=X)-是-C(=O)-时，R 不是苯基；或当存在成盐基团时，是其药学上可接受的盐；(B)二乙二醇的 C1-C4 烷基单醚，(C)胶凝剂和(D)与(B)混溶的溶剂。